Saturday, January 07, 2017 3:54:17 PM
My rational for holding is as follows;
Base Pipeline Revenue ROM
Focalin=3.8m
Effexor=4.4-2.2m
Protonix=5-1.2m
Glucophage=8-4.6m
Seroquel=6-4.1m
Lamictal=1.7-1.4m
Pristiq=8.6m
revenue 37.1-25.9m(low end)
S.o. 42m
Annual cost=-14m
P/e=16
Earnings per share= 0.55 to 0.42; times pe=16 ; price $8.8 to $4.5
Factoring in rexista 14.8m in rev.
Earnings per share with base=0.63 * 16=$10 a share
Company's rev and losses would be greater if manufacturering dosages but my ROM took a simplistically approach since manufacturing cost would be reimbursed.
Conclusion we'll get through $3 once potential dilution is resolved and another couple ANDAs approved.
Jan. 11 cash balance on hand should be interesting.we were at 4.1m.....
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM